TSX VENTURE: NVC
VANCOUVER, June 12, 2014 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the
"Company") (NASDAQ: NVCN) (TSXV: NVC) is pleased to announce that it
has been listed in the 2014 PROFIT 500 as one of Canada's fastest
growing companies. Having achieved an average revenue growth of
approximately 50% year over year since its inception in 2008, Neovasc
attributes its success to its strong customer relationships, attention
to operational excellence, and dedication to furthering advances in
cardiovascular device technology.
"We appreciate this recognition of our success and share the honour with
each of our employees, customers, shareholders, and industry partners
and offer our congratulations to all those named in this year's PROFIT
500," states Alexei Marko, CEO at Neovasc.
In addition to recently announcing strong clinical trial results for its
Reducer product for the treatment of refractory angina, the Company's
Tiara valve is now widely recognized as a leading program for
transcatheter mitral valve replacement. Neovasc's tissue development,
supply and manufacturing business provides services to a range of
customers around the world as a trusted provider of biological tissue
and cardiovascular device contract manufacturing services.
Published annually, the PROFIT 500 lists and profiles Canada's Fastest-Growing Companies by five-year revenue growth and gives entrepreneurs and their
businesses the recognition they deserve for their achievements and
contributions to Canada.
About PROFIT and PROFITguide.com
PROFIT: Your Guide to Business Success is Canada's preeminent media
brand dedicated to the management issues and opportunities facing small
and mid-sized businesses. For 32 years, Canadian entrepreneurs across a
vast array of economic sectors have remained loyal to PROFIT because
it's a timely and reliable source of actionable information that helps
them achieve business success and get the recognition they deserve for
generating positive economic and social change. Visit PROFIT online at
About Canadian Business
Founded in 1928, Canadian Business is the longest-serving, best-selling
and most-trusted business publication in the country. With a readership
of more than 800,000, it is the country's premier media brand for
executives and senior business leaders. It fuels the success of
Canada's business elite with a focus on the things that matter most:
leadership, innovation, business strategy and management tactics. We
provide concrete examples of business achievement, thought-provoking
analysis and compelling storytelling, all in an elegant package with
bold graphics and great photography. Canadian Businesswhat leadership
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Tiara technology
in development for the transcatheter treatment of mitral valve disease,
the Neovasc Reducer for the treatment of refractory angina and a line
of advanced biological tissue products that are used as key components
in third-party medical products including transcatheter heart valves.
For more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects,"
and "will" and words of similar import, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both nationally
and in the regions in which the Company operates; the merits and the
Company's defence of the lawsuit filed by CardiAQ, listing of the
Company's securities on the TSX, our anticipated use of proceeds from
any financings, a history of losses and lack of and uncertainty of
revenues, ability to obtain required financing, receipt of regulatory
approval of product candidates, ability to properly integrate newly
acquired businesses, technology changes; competition; changes in
business strategy or development plans; the ability to attract and
retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations;
liability and other claims asserted against the Company; and other
factors referenced in the Company's filings with Canadian securities
regulators. Although the Company believes that expectations conveyed by
the forward-looking statements are reasonable based on the information
available to it on the date such statements were made, no assurances
can be given as to the future results, approvals or achievements. Given
these uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as otherwise
required by applicable law.
SOURCE Neovasc Inc.